FENG; Yiqing
Patent Applications and Registrations
Patent applications and USPTO patent grants for FENG; Yiqing.The latest application filed is for "tigit and pd-1/tigit-binding molecules".
Company Profile
5.25.28
- FENG; Yiqing - Carmel IN
- Feng; Yiqing - Groton CT
- Feng; Yiqing - Wayne PA
- Feng; Yiqing - Spring House PA
- Feng; Yiqing - State College PA US
- Feng; Yiqing - Radnor PA US
- Feng; Yiqing - St. Louis MO
Patent Activity
| Patent | Date |
|---|---|
| Tigit And Pd-1/tigit-binding Molecules App 20220227860 - FENG; Yiqing ; et al. | 2022-07-21 |
| MET antibody drug conjugates Grant 11,167,039 - Feng , et al. November 9, 2 | 2021-11-09 |
| Bispecific Antibodies Targeting Immune Checkpoints App 20210292416 - DEMAREST; Stephen J. ; et al. | 2021-09-23 |
| Engineered Antibody Compounds and Conjuates Thereof App 20200155702 - Bacica; Michael James ; et al. | 2020-05-21 |
| Met Antibody Drug Conjugates App 20200061204 - FENG; Yiqing ; et al. | 2020-02-27 |
| PD-1 agonist antibodies and uses thereof Grant 10,493,148 - Yachi , et al. De | 2019-12-03 |
| Cyclic Peptides As C5a Receptor Antagonists App 20190270778 - Che; Ye ; et al. | 2019-09-05 |
| Pd-1 Agonist Antibodies And Uses Thereof App 20190270818 - Yachi; Pia Pauliina ; et al. | 2019-09-05 |
| Toll-like Receptor 3 Antagonists App 20180179294 - Cunningham; Mark ; et al. | 2018-06-28 |
| Methods of reducing clinical symptoms of viral infection by administering a toll-like receptor 3 antagonist Grant 9,932,404 - Cunningham , et al. April 3, 2 | 2018-04-03 |
| Toll-Like Receptor 3 Antagonists App 20170058041 - Cunningham; Mark ; et al. | 2017-03-02 |
| Method of treating an inflammatory condition by administering toll-like 3 receptor antagonists Grant 9,522,957 - Cunningham , et al. December 20, 2 | 2016-12-20 |
| Boron-containing small molecules as anti-protozoal agents Grant 9,493,489 - Jacobs , et al. November 15, 2 | 2016-11-15 |
| Toll-like receptor 3 antagonists Grant 9,481,731 - Cunningham , et al. November 1, 2 | 2016-11-01 |
| Polynucleotides encoding Toll-Like Receptor 3 antagonists Grant 9,255,153 - Cunningham , et al. February 9, 2 | 2016-02-09 |
| Method of treating asthma or reducing inflammatory cell lung inflammation by administering toll-like receptor 3 antibodies Grant 9,238,693 - Cunningham , et al. January 19, 2 | 2016-01-19 |
| Toll-Like Receptor 3 Antagonists App 20140212426 - Cunningham; Mark ; et al. | 2014-07-31 |
| Toll-Like 3 Receptor Antagonists App 20140093508 - Cunningham; Mark ; et al. | 2014-04-03 |
| Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases App 20140017250 - Cunningham; Mark ; et al. | 2014-01-16 |
| Toll-Like Receptor 3 Antagonists App 20130280263 - Cunningham; Mark ; et al. | 2013-10-24 |
| Toll-like receptor 3 antagonists Grant 8,540,986 - Cunningham , et al. September 24, 2 | 2013-09-24 |
| Toll-Like Receptor 3 Antagonists App 20130244281 - Cunningham; Mark ; et al. | 2013-09-19 |
| Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases Grant 8,460,659 - Cunningham , et al. June 11, 2 | 2013-06-11 |
| Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases App 20130090457 - Cunningham; Mark ; et al. | 2013-04-11 |
| Toll-like receptor 3 antagonists Grant 8,409,567 - Cunningham , et al. April 2, 2 | 2013-04-02 |
| Engineered anti-IL-13 antibodies, compositions, methods and uses Grant 8,399,630 - Swanson , et al. March 19, 2 | 2013-03-19 |
| Toll-like Receptor 3 Antagonists For The Treatment Of Metabolic And Cardiovascular Diseases App 20120064095 - Cunningham; Mark ; et al. | 2012-03-15 |
| Engineered Anti-il-13 Antibodies, Compositions, Methods And Uses App 20120045438 - Swanson; Ronald V. ; et al. | 2012-02-23 |
| Boron-containing Small Molecules As Anti-protozoal Agents App 20110207702 - Jacobs; Robert ; et al. | 2011-08-25 |
| Toll-Like Receptor 3 Antagonists App 20110008352 - Cunningham; Mark ; et al. | 2011-01-13 |
| Toll-Like Receptor 3 Antagonists App 20100166778 - Cunningham; Mark ; et al. | 2010-07-01 |
| Multi-functional chimeric hematopoietic receptor agonists App 20070081979 - Mc Kearn; John P. ; et al. | 2007-04-12 |
| Novel erythropoietin receptor agonists App 20060172932 - Summers; Neena L. ; et al. | 2006-08-03 |
| Multi-functional chimeric hematopoietic receptor agonists Grant 6,967,092 - Mc Kearn , et al. November 22, 2 | 2005-11-22 |
| Multi-functional hematopoietic fusion proteins between sequence rearranged G-CSF receptor agonists and other hematopoietic factors App 20040171115 - Feng, Yiqing ; et al. | 2004-09-02 |
| Circular permuteins of flt3 ligand App 20040127410 - McWherter, Charles A. ; et al. | 2004-07-01 |
| Fused G-CSF and IL-3 proteins and uses thereof Grant 6,730,303 - Feng , et al. May 4, 2 | 2004-05-04 |
| Circular permuteins of flt3 ligand Grant 6,660,257 - McWherter , et al. December 9, 2 | 2003-12-09 |
| G-CSF receptor agonists Grant 6,100,070 - Zurfluh , et al. August 8, 2 | 2000-08-08 |
| Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors Grant 6,066,318 - Feng , et al. May 23, 2 | 2000-05-23 |
| Stem cell factor receptor agonists Grant 5,969,105 - Feng , et al. October 19, 1 | 1999-10-19 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 